Literature DB >> 17192164

Therapeutic options for sleep-maintenance and sleep-onset insomnia.

Anna K Morin1, Courtney I Jarvis, Ann M Lynch.   

Abstract

Insomnia, defined as difficulty falling asleep, staying asleep, and/or experiencing restorative sleep with associated impairment or significant distress, is a common condition resulting in significant clinical and economic consequences. Many options are available to treat insomnia, to assist with either falling asleep (sleep onset) or maintaining sleep. We searched MEDLINE for articles published between January 1996 and January 2006, evaluated abstracts from recent professional meetings, and contacted the manufacturer of the most recent addition to the pharmacologic armamentarium for insomnia treatment (ramelteon) to gather information. Nonpharmacologic options include stimulus control, sleep hygiene education, sleep restriction, paradoxical intention, relaxation therapy, biofeedback, and cognitive behavioral therapy. Prescription and over-the-counter drug therapies include benzodiazepine and nonbenzodiazepine sedative-hypnotic agents; ramelteon, a melatonin receptor agonist; trazodone; and sedating antihistamines. Herbal and alternative preparations include melatonin and valerian. Before recommending any treatment, clinicians should consider patient-specific criteria such as age, medical history, and other drug use, as well as the underlying cause of the sleep disturbance. All pharmacotherapy should be used with appropriate caution, at minimum effective doses, and for minimum duration of time.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17192164     DOI: 10.1592/phco.27.1.89

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  24 in total

Review 1.  Use of ultra-low-dose (≤6 mg) doxepin for treatment of insomnia in older people.

Authors:  Carlos H Rojas-Fernandez; Yannan Chen
Journal:  Can Pharm J (Ott)       Date:  2014-09

2.  Therapies for insomnia and comorbid chronic obstructive pulmonary disease with a focus on ramelteon (rozerem).

Authors:  Jack Greenberg; J B Goss
Journal:  P T       Date:  2009-09

3.  Analysis of spatiotemporal pattern and quantification of gastrointestinal slow waves caused by anticholinergic drugs.

Authors:  Kelvin K L Wong; Lauren C Y Tang; Jerry Zhou; Vincent Ho
Journal:  Organogenesis       Date:  2017-02-23       Impact factor: 2.500

Review 4.  Interactions between disordered sleep, post-traumatic stress disorder, and substance use disorders.

Authors:  Ryan Vandrey; Kimberly A Babson; Evan S Herrmann; Marcel O Bonn-Miller
Journal:  Int Rev Psychiatry       Date:  2014-04

5.  Mild cognitive impairment: associations with sleep disturbance, apolipoprotein e4, and sleep medications.

Authors:  Shanna L Burke; Tianyan Hu; Christine E Spadola; Tan Li; Mitra Naseh; Aaron Burgess; Tamara Cadet
Journal:  Sleep Med       Date:  2018-09-20       Impact factor: 3.492

6.  The sedating antidepressant trazodone impairs sleep-dependent cortical plasticity.

Authors:  Sara J Aton; Julie Seibt; Michelle C Dumoulin; Tammi Coleman; Mia Shiraishi; Marcos G Frank
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

7.  One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue.

Authors:  Ann M Berger; Brett R Kuhn; Lynne A Farr; Susanna G Von Essen; Julie Chamberlain; James C Lynch; Sangeeta Agrawal
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

8.  Anticholinergic Exposure During Rehabilitation: Cognitive and Physical Function Outcomes in Patients with Delirium Superimposed on Dementia.

Authors:  Ann Kolanowski; Jacqueline Mogle; Donna M Fick; Noll Campbell; Nikki Hill; Paula Mulhall; Liza Behrens; Elise Colancecco; Malaz Boustani; Linda Clare
Journal:  Am J Geriatr Psychiatry       Date:  2015-07-31       Impact factor: 4.105

9.  A randomized phase II trial evaluating two non-pharmacologic interventions in cancer survivors for the treatment of sleep-wake disturbances: NCCTG N07C4 (Alliance).

Authors:  Debra L Barton; Pamela J Atherton; Daniel V Satele; Rui Qin; Shaker Dakhil; Teri Pipe; Timothy Hobday; Kelli Fee-Schroeder; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2020-04-19       Impact factor: 3.603

10.  Indiplon in the management of insomnia.

Authors:  Michael D Lemon; Joe D Strain; Annie M Hegg; Debra K Farver
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.